TY - JOUR
T1 - Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability
AU - Chong, Suet Yen
AU - Wang, Xiaoyuan
AU - van Bloois, Louis
AU - Huang, Chenyuan
AU - Syeda, Nilofer Sayed
AU - Zhang, Sitong
AU - Ting, Hui Jun
AU - Nair, Vaarsha
AU - Lin, Yuanzhe
AU - Lou, Charles Kang Liang
AU - Benetti, Ayca Altay
AU - Yu, Xiaodong
AU - Lim, Nicole Jia Ying
AU - Tan, Michelle Siying
AU - Lim, Hwee Ying
AU - Lim, Sheau Yng
AU - Thiam, Chung Hwee
AU - Looi, Wen Donq
AU - Zharkova, Olga
AU - Chew, Nicholas W.S.
AU - Ng, Cheng Han
AU - Bonney, Glenn Kunnath
AU - Muthiah, Mark
AU - Chen, Xiaoyuan
AU - Pastorin, Giorgia
AU - Richards, A. Mark
AU - Angeli, Veronique
AU - Storm, Gert
AU - Wang, Jiong Wei
N1 - Publisher Copyright:
© 2023
PY - 2023/8
Y1 - 2023/8
N2 - Atherosclerosis is a chronic inflammatory vascular disease that is characterized by the accumulation of lipids and immune cells in plaques built up inside artery walls. Docosahexaenoic acid (DHA, 22:6n-3), an omega-3 polyunsaturated fatty acid (PUFA), which exerts anti-inflammatory and antioxidant properties, has long been purported to be of therapeutic benefit to atherosclerosis patients. However, large clinical trials have yielded inconsistent data, likely due to variations in the formulation, dosage, and bioavailability of DHA following oral intake. To fully exploit its potential therapeutic effects, we have developed an injectable liposomal DHA formulation intended for intravenous administration as a plaque-targeted nanomedicine. The liposomal formulation protects DHA against chemical degradation and increases its local concentration within atherosclerotic lesions. Mechanistically, DHA liposomes are readily phagocytosed by activated macrophages, exert potent anti-inflammatory and antioxidant effects, and inhibit foam cell formation. Upon intravenous administration, DHA liposomes accumulate preferentially in atherosclerotic lesional macrophages and promote polarization of macrophages towards an anti-inflammatory M2 phenotype, resulting in attenuation of atherosclerosis progression in both ApoE−/− and Ldlr−/− experimental models. Plaque composition analysis demonstrates that liposomal DHA inhibits macrophage infiltration, reduces lipid deposition, and increases collagen content, thus improving the stability of atherosclerotic plaques against rupture. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) further reveals that DHA liposomes can partly restore the complex lipid profile of the plaques to that of early-stage plaques. In conclusion, DHA liposomes offer a promising approach for applying DHA to stabilize atherosclerotic plaques and attenuate atherosclerosis progression, thereby preventing atherosclerosis-related cardiovascular events.
AB - Atherosclerosis is a chronic inflammatory vascular disease that is characterized by the accumulation of lipids and immune cells in plaques built up inside artery walls. Docosahexaenoic acid (DHA, 22:6n-3), an omega-3 polyunsaturated fatty acid (PUFA), which exerts anti-inflammatory and antioxidant properties, has long been purported to be of therapeutic benefit to atherosclerosis patients. However, large clinical trials have yielded inconsistent data, likely due to variations in the formulation, dosage, and bioavailability of DHA following oral intake. To fully exploit its potential therapeutic effects, we have developed an injectable liposomal DHA formulation intended for intravenous administration as a plaque-targeted nanomedicine. The liposomal formulation protects DHA against chemical degradation and increases its local concentration within atherosclerotic lesions. Mechanistically, DHA liposomes are readily phagocytosed by activated macrophages, exert potent anti-inflammatory and antioxidant effects, and inhibit foam cell formation. Upon intravenous administration, DHA liposomes accumulate preferentially in atherosclerotic lesional macrophages and promote polarization of macrophages towards an anti-inflammatory M2 phenotype, resulting in attenuation of atherosclerosis progression in both ApoE−/− and Ldlr−/− experimental models. Plaque composition analysis demonstrates that liposomal DHA inhibits macrophage infiltration, reduces lipid deposition, and increases collagen content, thus improving the stability of atherosclerotic plaques against rupture. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) further reveals that DHA liposomes can partly restore the complex lipid profile of the plaques to that of early-stage plaques. In conclusion, DHA liposomes offer a promising approach for applying DHA to stabilize atherosclerotic plaques and attenuate atherosclerosis progression, thereby preventing atherosclerosis-related cardiovascular events.
KW - Atherosclerosis
KW - Cardiovascular disease
KW - DHA
KW - Inflammation
KW - Liposomes
KW - M2 macrophages
KW - Omega-3 polyunsaturated fatty acid
KW - Plaque vulnerability
UR - http://www.scopus.com/inward/record.url?scp=85164213593&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2023.06.035
DO - 10.1016/j.jconrel.2023.06.035
M3 - Article
C2 - 37406819
AN - SCOPUS:85164213593
SN - 0168-3659
VL - 360
SP - 344
EP - 364
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -